Enter the text here that is the new abstract information for your application. This section must be no longer than 30 lines of text. Since the advent of point-of-care diagnostics (POCD) several decades ago, one class of novel medical technologies that has shown promise for POCD applications is microsystems diagnostics--microchip-enabled tests ranging from microelectromechanical systems (MEMs)-based sensors, microfluidics, to smartphone-based systems. Notable for their small size, low power requirements, and high sensitivity, microsystems provide portability that is vital for POCD testing. Since 2018, the Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT) has assisted inventors who have developed microsystems-based POCD technologies in defining their specific clinical needs, conducting clinical validation, and refining their technology, with the objective of accelerating the path to translation and clinical adoption. The ACME POCT uniquely leverages Atlanta’s nationally top-ranked clinical programs at Emory’s hospitals and Children’s Healthcare of Atlanta (CHOA), one of the nation’s largest pediatric hospital systems, as well the internationally acclaimed microsystems expertise at Georgia Tech, which includes the Institute for Matter and Systems (IMS). The PIs of the ACME POCT uniquely balance the engineering and clinical sides of the Center and comprise Wilbur Lam, MD, PhD, a pediatrician at Emory/CHOA and a Georgia Tech bioengineer with a personal track record in microfluidics and point-of-care diagnostic development and commercialization; Eric Vogel, PhD, a renowned materials science and engineering expert, and head of Georgia Tech’s IMS; and Greg Martin, MD, MSc, an internationally known clinical pulmonologist/intensivist at Emory with system-level clinical research leadership experience. Over the last 4 years, the ACME POCT has applied a “disease inclusive” approach by fostering the development of 22 microsystems-based POCD technologies for all clinical applications. As the COVID-19 pandemic emerged and the NIH established the Rapid Acceleration of Diagnostics (RADx) initiative to assess, validate, and scale-up production of POCD for COVID-19 for the entire country, the ACME POCT served as the national Test Verification Core. As such, the ACME POCT established itself as a center of excellence in diagnostics evaluation by developing an efficient yet comprehensive test verification strategy by progressively assessing technologies in various laboratory then clinical settings, with parallel assessments of usability and regulatory strategy. Importantly, our Atlanta bio-innovation ecosystem has also flourished, including the launch of an Emory-based center that is dedicated to developing POCD tests for all, and a program that develops clinical mobile apps, often as companion technologies for POCD. With our distinctive role in RADx combined with our uniquely enhanced expertise, ecosystem and infrastructures, the ACME P...